NEXTCURE INC (NXTC)
US65343E1082 - Common Stock
We assign a fundamental rating of 2 out of 10 to NXTC. NXTC was compared to 564 industry peers in the Biotechnology industry. While NXTC seems to be doing ok healthwise, there are quite some concerns on its profitability. NXTC has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
NXTC had negative earnings in the past year.
NXTC had a negative operating cash flow in the past year.
NXTC had negative earnings in each of the past 5 years.
In the past 5 years NXTC always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -64.77%, NXTC is doing worse than 63.02% of the companies in the same industry.
NXTC has a Return On Equity (-77.41%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.77% | ||
| ROE | -77.41% | ||
| ROIC | N/A |
ROA(3y)-39.39%
ROA(5y)-27.92%
ROE(3y)-43.05%
ROE(5y)-30.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NXTC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for NXTC has been increased compared to 1 year ago.
The number of shares outstanding for NXTC has been increased compared to 5 years ago.
There is no outstanding debt for NXTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -6.06, we must say that NXTC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.06, NXTC is not doing good in the industry: 67.15% of the companies in the same industry are doing better.
There is no outstanding debt for NXTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.06 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 9.07 indicates that NXTC has no problem at all paying its short term obligations.
The Current ratio of NXTC (9.07) is better than 77.92% of its industry peers.
NXTC has a Quick Ratio of 9.07. This indicates that NXTC is financially healthy and has no problem in meeting its short term obligations.
NXTC has a Quick ratio of 9.07. This is in the better half of the industry: NXTC outperforms 77.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.07 | ||
| Quick Ratio | 9.07 |
3. Growth
3.1 Past
NXTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.06%, which is quite good.
EPS 1Y (TTM)11.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
NXTC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.20% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.36%
EPS Next 2Y16.33%
EPS Next 3Y19.79%
EPS Next 5Y12.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NXTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NXTC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NXTC's earnings are expected to grow with 19.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.33%
EPS Next 3Y19.79%
5. Dividend
5.1 Amount
No dividends for NXTC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEXTCURE INC
NASDAQ:NXTC (1/3/2025, 8:00:02 PM)
0.8225
+0 (+0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners53.71%
Inst Owner Change-0.9%
Ins Owners1.81%
Ins Owner Change0%
Market Cap23.04M
Analysts80
Price Target3.57 (334.04%)
Short Float %0.21%
Short Ratio0.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.83%
Min EPS beat(2)-43.15%
Max EPS beat(2)-16.51%
EPS beat(4)1
Avg EPS beat(4)-20.93%
Min EPS beat(4)-43.15%
Max EPS beat(4)5.9%
EPS beat(8)4
Avg EPS beat(8)-6.3%
EPS beat(12)6
Avg EPS beat(12)-3.59%
EPS beat(16)8
Avg EPS beat(16)-1.98%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5%
PT rev (3m)-30%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.3 | ||
| P/tB | 0.3 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.09
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0
BVpS2.7
TBVpS2.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.77% | ||
| ROE | -77.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-39.39%
ROA(5y)-27.92%
ROE(3y)-43.05%
ROE(5y)-30.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 17.18% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.07 | ||
| Quick Ratio | 9.07 | ||
| Altman-Z | -6.06 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)43.39%
Cap/Depr(5y)92.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.61%
EPS Next Y12.36%
EPS Next 2Y16.33%
EPS Next 3Y19.79%
EPS Next 5Y12.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.81%
OCF growth 3YN/A
OCF growth 5YN/A